For research use only
| Cat No. | ABC-X0042C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Lymphocyte |
| Species | Human |
| Host Cell | BAF3 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Storage | Liquid Nitrogen |
The NRAS (G13S) BAF3 cell line provides an ideal model for studying tumor biology and RAS/MAPK pathway inhibitors, supporting genomics research.
Human NRAS (G13S) BAF3 Cell Line is a genetically engineered model derived from selected murine Ba/F3 parental cell line based on customers’ requirement. NRAS (G13S) BAF3 mutant cell line is generated by stable integration of exogenous human NRAS gene harboring the G13S mutation into Ba/F3 host cells using our optimized transduction of lentiviral vectors.
Target
NRAS is a key small GTPase regulating intracellular signaling cascades such as RAF/MEK/ERK and PI3K/AKT pathways. The G13S mutation disrupts intrinsic GTPase activity, resulting in constitutive activation of downstream effectors and enhanced proliferative signaling. This mutation has been identified in various solid tumors and hematologic cancers. AcceGen offers custom-generated mutant models to facilitate oncogenic pathway research and therapeutic development. Polyclonal or monoclonal is optional based on customers’ research needs.
| Species | Human |
| Cat.No | ABC-X0042C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocyte |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO₂ |
| Source Organ | Lymphatic |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | BAF3 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
The NRAS (G13S) BAF3 Cell Line is a valuable tool for investigating RAS-driven malignancies, studying IL-3-independent growth, and testing RAS/MAPK pathway inhibitors. It supports functional genomics, resistance mechanism analysis, and precision oncology efforts.